Justin Zelin
Stock Analyst at BTIG
(n/a)
# 3,234
Out of 4,786 analysts
37
Total ratings
n/a
Success rate
-30.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $3.01 | +99.34% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $19.68 | +113.41% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.31 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $16.38 | +278.51% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $4.30 | +1,993.02% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.38 | +769.57% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $0.13 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $24.15 | +417.60% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $6.03 | +347.76% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.25 | +63,900.00% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $29.67 | +206.71% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.76 | +1,224.50% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.88 | +1,726.07% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $7.27 | +408.94% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $12.29 | +184.90% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $33.93 | +165.25% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.60 | +369.70% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $69.44 | -77.68% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.19 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $2.16 | +362.96% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $3.01
Upside: +99.34%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $19.68
Upside: +113.41%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.31
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $16.38
Upside: +278.51%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $4.30
Upside: +1,993.02%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.38
Upside: +769.57%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.13
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $24.15
Upside: +417.60%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $6.03
Upside: +347.76%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.25
Upside: +63,900.00%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $29.67
Upside: +206.71%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.76
Upside: +1,224.50%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.88
Upside: +1,726.07%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $7.27
Upside: +408.94%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $12.29
Upside: +184.90%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $33.93
Upside: +165.25%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.60
Upside: +369.70%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $69.44
Upside: -77.68%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.19
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $2.16
Upside: +362.96%